Apyx Medical Corporation provided earnings guidance for the year ending December 31, 2024. For the year, the company expects Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December 31, 2023. Net loss attributable to stockholders of approximately $26.5 million to $24.3 million, compared to $18.7 million for the year ended December 31, 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 USD | -2.21% | -8.90% | -49.24% |
May. 09 | Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.24% | 47.12M | |
-3.82% | 181B | |
-3.05% | 105B | |
-2.68% | 67.55B | |
-6.41% | 46.39B | |
+4.82% | 40.93B | |
+20.35% | 31.63B | |
+12.18% | 24.28B | |
-6.85% | 23.46B | |
-12.93% | 21.95B |
- Stock Market
- Equities
- APYX Stock
- News Apyx Medical Corporation
- Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024